Stockreport

Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next [Yahoo! Finance]

Edgewise Therapeutics, Inc.  (EWTX) 
PDF dystrophy, showing sustained stabilization of patient function over 3.5 years and a continued favorable safety profile. An unusually high 99% of eligible participants [Read more]